Stock IVA INVENTIVA
Add to a list
To use this feature you must be a member
Log inSign up

News Inventiva

Equities

IVA

FR0013233012

Real-time Euronext Paris
Other stock markets
 09:30:21 2024-04-16 am EDT 		5-day change 1st Jan Change
3.105 EUR -7.04% Intraday chart for Inventiva -13.27% -24.18%
Apr. 08 Canaccord Genuity Adjusts Price Target on Inventiva to $20 From $12, Maintains Buy Rating MT
Apr. 08 INVENTIVA : Canaccord Genuity raises target CF

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Canaccord Genuity Adjusts Price Target on Inventiva to $20 From $12, Maintains Buy Rating
MT
INVENTIVA : Canaccord Genuity raises target
CF
Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F
GL
Transcript : Inventiva S.A., 2023 Earnings Call, Mar 28, 2024
Inventiva announces the nomination of Andre Turenne as Director
GL
Inventiva S.A. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Inventiva reports its 2023 full-year results
GL
Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results
GL
ADRs End Flat, Ehang Holdings Ltd. Climbs 15.6%
DJ
Transcript : Inventiva S.A. - Special Call
Inventiva: positive results from phase 2 clinical trial
CF
Inventiva S.A. Announces Positive Results from the Phase II, Legend, Proof-Of-Concept Study Combining Lanifibranor with Empagliflozin
CI
Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D
GL
Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D
AQ
Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D
GL
Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D
AQ
Inventiva: NATiV3 study pause lifted
CF
Inventiva Resumes Patient Recruitment for Lanifibranor Clinical Trial
MT
Inventiva Announces Voluntary Pause on Screening and Randomization of Its NATiV3 clinical trial
CI
Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IVA Stock
  4. News Inventiva